EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

ClinicalTrials.gov ID: NCT02234843

Public ClinicalTrials.gov record NCT02234843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

Study identification

NCT ID: NCT02234843
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 500 participants

Conditions and interventions

Conditions

Venous Thromboembolism

Interventions

Rivaroxaban (Xarelto, BAY59-7939) Drug
Standard of Care Drug

Drug

Eligibility (public fields only)

Age range: Up to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 13, 2014 (Actual)
Primary completion: Jan 30, 2019 (Actual)
Completion: Jan 30, 2019 (Actual)
Last update posted: Apr 1, 2020

2014 – 2019

United States locations

U.S. sites: 23
U.S. states: 13
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85016	—
Not listed	Little Rock	Arkansas	72202-3500	—
Not listed	Los Angeles	California	90027-6089	—
Not listed	Los Angeles	California	90095	—
Not listed	San Diego	California	92123	—
Not listed	Gainesville	Florida	32610	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Miami	Florida	33155	—
Not listed	Pensacola	Florida	32504	—
Not listed	St. Petersburg	Florida	33701	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Chicago	Illinois	60611	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Lansing	Michigan	48912	—
Not listed	Kansas City	Missouri	64108-9898	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cincinnati	Ohio	45229-3039	—
Not listed	Cleveland	Ohio	44106-2602	—
Not listed	Columbus	Ohio	43205-2696	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Dallas	Texas	75235	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02234843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 1, 2020 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02234843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →